# US 2021/0069339 A1 · Cnp prodrugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069339 A1
- Document ID: US20210069339A1
- Status: Published application
- Kind: A1
- Application number: 16/993,127
- Filed: 2020-08-13
- Published: 2021-03-11
- Earliest claimed: 2015-01-09
- Assignees: Ascendis Pharma Growth Disorders A/S
- Applicants: Ascendis Pharma Growth Disorders A/S
- Inventors: Kennett Sprogøe; Ulrich Hersel; Harald Rau; Thomas Wegge; Frank Faltinger; Felix Cleemann; Nora Kaluza; Ana Bernhard; Annette Buba; Tom Woods
- Web page: https://patentgrep.com/patent/US20210069339A1

## CPC

- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/22: Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35)
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 5/10: of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P 17/00: Drugs for dermatological disorders
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to prodrugs of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising such CNP prodrugs and their uses. In an embodiment, the CNP prodrugs are conjugates of CNP peptides to poly(ethylene glycol) through a reversible linker.

## Claims

### Claim 1

A CNP prodrug or a pharmaceutically acceptable salt thereof, wherein the prodrug is of formula (Ia) or (Ib)
ZL2-L1-D)x (Ia)
DL1-L2-Z)y (Ib),
wherein
-D is a CNP moiety;
-L1- is a reversible prodrug linker moiety;
-L2- is a single chemical bond or a spacer moiety;
—Z is a water-soluble carrier moiety;
x is an integer selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 16; and
y is an integer selected from the group consisting of 1, 2, 3, 4 and 5.

### Claim 2

A CNP prodrug or a pharmaceutically acceptable salt thereof comprising a conjugate D-L, wherein
-D is a CNP moiety; and
-L comprises a reversible prodrug linker moiety -L1-;
wherein -L1- is substituted with -L2-Z′ and is optionally further substituted; wherein
-L2- is a single chemical bond or a spacer moiety; and
—Z′ is a water-insoluble carrier moiety.

### Claim 3 (depends on 2)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 2, wherein —Z′ is a hydrogel.

### Claim 4 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein the CNP prodrug is of formula (Ia).

### Claim 5 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein x is 1.

### Claim 6 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein CNP moiety has the sequence of SEQ ID NO:25 or SEQ ID NO:24.

### Claim 7 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein the CNP moiety has the sequence of SEQ ID NO:24.

### Claim 8 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -L1- is conjugated to the side chain of an amino acid residue of the ring moiety of -D or to the backbone of the ring moiety of -D.

### Claim 9 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -L1- is conjugated to the side chain of an amino acid residue of the ring moiety of -D selected from the group consisting of histidine, lysine, tryptophan, serine, threonine, tyrosine, aspartic acid, glutamic acid and arginine.

### Claim 10 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein -D has the sequence of SEQ ID NO:24 and -L1- is conjugated to the lysine at position 26 of -D.

### Claim 11 (depends on 1)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 1, wherein the moiety -L1- is of formula (II):
wherein the dashed line indicates the attachment to a nitrogen of -D which is a CNP moiety by forming an amide bond;
—X— is —C(R4R4a)—; —N(R4)—; —O—; —C(R4R4a)—C(R5R5a)—; —C(R5R5a)—C(R4R4a)—; —C(R4R4a)—N(R6)—; —N(R6)—C(R4R4a)—; —C(R4R4a)—O—; —O—C(R4R4a)—; or —C(R7R7a)—;
X1 is C; or S(O);
—X2— is —C(R8R8a)—; or —C(R8R8a)—C(R9R9a)—;
═X3 is ═O; ═S; or ═N—CN;
—R1, —R1a, —R2, —R2a, —R4, —R4a, —R5, —R5a, —R6, —R8, —R8a, —R9, —R9a are independently selected from the group consisting of —H; and C1-6 alkyl;
—R3, —R3a are independently selected from the group consisting of —H; and C1-6 alkyl, provided that in case one of —R3, —R3a or both are other than —H they are connected to N to which they are attached through an SP3-hybridized carbon atom;
—R7 is —N(R10R10a); or —NR10—(C═O)—R11;
—R7a, —R10, —R10a, —R11 are independently of each other —H; or C1-6 alkyl;
optionally, one or more of the pairs -R1a/—R4a, —R1a/—R5a, —R1a/—R7a, —R4a/—R5a, —R8a/—R9a form a chemical bond;
optionally, one or more of the pairs -R1/R1a, —R2/—R2a, —R4/—R4a, —R5/—R5a, —R8/—R8a, —R9/—R9a are joined together with the atom to which they are attached to form a C3-10 cycloalkyl; or 3- to 10-membered heterocyclyl;
optionally, one or more of the pairs -R1/R4, —R1/R5, —R1/R6, —R1/R7a, —R4/—R5, —R4/—R6, —R8/—R9, —R2/—R3 are joined together with the atoms to which they are attached to form a ring A;
optionally, R3/R3a are joined together with the nitrogen atom to which they are attached to form a 3- to 10-membered heterocycle;
A is selected from the group consisting of phenyl; naphthyl; indenyl; indanyl; tetralinyl; C3-10 cycloalkyl; 3- to 10-membered heterocyclyl; and 8- to 11-membered heterobicyclyl; and
wherein -L1- is substituted with -L2-Z or -L2-Z′ and wherein -L1- is optionally further substituted, provided that the hydrogen marked with the asterisk in formula (II) is not replaced by -L2-Z or -L2-Z′ or a substituent;
wherein
-L2- is a single chemical bond or a spacer;
—Z is a water-soluble carrier; and
—Z′ is a water-insoluble carrier.

### Claim 12 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —X— is —C(R4R4a)— or —N(R4)—.

### Claim 13 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —R4 is substituted with -L2-Z or -L2-Z′.

### Claim 14 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein X1 is C.

### Claim 15 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein ═X3 is ═O.

### Claim 16 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —X2— is —C(R8R8a)—.

### Claim 17 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —R1 and —R1a are —H.

### Claim 18 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —R2 and —R2a are —H.

### Claim 19 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —R3 is —H and —R3a is methyl.

### Claim 20 (depends on 11)

The CNP prodrug or a pharmaceutically acceptable salt thereof of claim 11, wherein —R4 and —R4a are —H.

### Claim at position 21

21-59. (canceled)
